Skip to main content
Premium Trial:

Request an Annual Quote

ReachBio to Distribute Axiogenesis Cell Analysis Products in North America

NEW YORK (GenomeWeb News) – Seattle-based ReachBio today said that it would distribute Axiogenesis' full product line to the North American life science research and drug discovery markets.
Cologne-based Axiogenesis sells tissue-specific cells derived from specially engineered mouse stem cell lines that are used in basic research, drug discovery, and toxicity testing of new drug candidates. According to a ReachBio statement, the first cell types available from Axiogenesis are pure atrial cardiomyocytes used for cardiotoxicity screening, electrophysiology studies, and as a cellular model system for hypertrophic cardiomyopathy.
Heribert Bohlen, CEO of Axiogenesis, said in a statement that ReachBio “share[s] our philosophy that cellular model systems for drug discovery and toxicity testing should utilize highly relevant cells that are as close to the natural state as possible. The biopharma industry is trying to find ways to move away from the use of artificial cell lines that have questionable biological significance in the drug development process, and towards more biologically relevant cellular systems.”
Terms of the agreement were not disclosed.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.